Page 7 of 8
and were stable for several months before starting the study, while those in the DTG
and 3TC group had started new medicines.
This was a phase III study. Phase III studies collect information about how well new
medicines work and how safe they are. The results help government regulators decide
whether to approve new medicines for their country.
Are there plans for further studies?
Other studies of DTG and 3TC in adults living with HIV have been completed. Some are
ongoing or planned.
Where can I find more information about this study?
Clinical studies have unique study numbers that are included in publications and other
information about the study. The unique study numbers associated with this study are
shown below with internet links to scientific summaries.
The scientific summaries include more details about the requirements for study
enrolment, the study visit schedule, results from other outcomes, and more detailed
information about adverse events. When the study is complete, final results will be
available in the scientific summaries.
Organisation and Website Study Number
European Medicines Agency
2015-004401-171
(www.clinicaltrialsregister.eu)
United States National Institutes of Health (NIH)
NCT034465732
(www.clinicaltrials.gov)
Your doctor or healthcare provider can help you understand more about this study and
the results. Speak to your doctor about the treatment options available in your
country. You should not make changes to your care based on the results of this or any
single study. Keep taking your current treatment unless instructed by your doctor.
We would like to thank the participants who made this study possible. The results of
this study will help answer scientific questions about treating adults living with HIV.
1https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004401-17
2https://clinicaltrials.gov/ct2/show/NCT03446573